LEADER 03316nam  2200961z- 450 
001 9910557610103321
005 20231214133507.0
035   $a(CKB)5400000000045301
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/79654
035   $a(EXLCZ)995400000000045301
100   $a20202203d2022      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aPharmacogenetics to Avoid Adverse Drug Reactions
210   $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022
215   $a1 electronic resource (220 p.)
311   $a3-0365-3344-3 
311   $a3-0365-3343-5 
330   $aAdverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This book delves into new advances in pharmacogenetics of cardiovascular, cancer, and nervous system drugs. It may be useful for clinicians and patients to understand the basics of pharmacogenetics.
606   $aMedicine$2bicssc
610   $a5-fluorouracil
610   $acapecitabine
610   $afluoropyrimidine
610   $athymidylate synthase
610   $athymidylate synthase enhancer region
610   $aupstream stimulatory factor 1
610   $aadverse drug reactions
610   $apharmacogenomics
610   $aepistasis
610   $arandom forest
610   $astatin
610   $acardiovascular disease
610   $acolorectal cancer
610   $apersonalised medicine
610   $atoxicity
610   $a(es)citalopram
610   $adrug-gene-interaction
610   $adrug-drug-interaction
610   $adrug-drug-gene-interaction
610   $athe PharmLines initiative
610   $aantipsychotic agents
610   $apharmacogenetics
610   $acytochrome P-450 enzyme system
610   $apsychotic disorders
610   $aprecision medicine
610   $adirect oral anticoagulants
610   $aclinical implementation
610   $aatorvastatin
610   $aSLCO1B1
610   $aHLA
610   $acutaneous adverse drug reaction
610   $aSCAR
610   $agenetic polymorphism
610   $aantiepileptics
610   $aCYP450 enzymes
610   $aplatelet reactivity
610   $asingle-nucleotide variants
610   $aacute coronary syndrome
610   $aclopidogrel
610   $agenotype
610   $aallele
610   $apolymorphism
610   $aHLA B
610   $aCYP2C9*3
610   $acutaneous adverse drug reactions (CADRs)
610   $aanti-epileptic drugs (AEDS)
610   $aphenytoin (PHT)
610   $agenetic risk factors
610   $aSouth India
610   $aIndia
610   $acardiology
610   $aadverse events
610   $aguidelines
615  7$aMedicine
700   $aLo?pez-Ferna?ndez$b Luis A$4edt$01319399
702   $aLo?pez-Ferna?ndez$b Luis A$4oth
906   $aBOOK
912   $a9910557610103321
996   $aPharmacogenetics to Avoid Adverse Drug Reactions$93033877
997   $aUNINA